查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1559552

全球内分泌检测市场

Endocrine Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 168 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2030年全球内分泌检测市场预计将达169亿美元

全球内分泌检测市场预计 2023 年为 120 亿美元，预计到 2030 年将达到 169 亿美元，2023 年至 2030 年复合年增长率为 5.0%。串联式质谱质谱技术是本报告分析的细分市场之一，预计复合年增长率为 6.2%，到分析期结束时将达到 53 亿美元。分析期内，免疫测量技术领域的复合年增长率预计为5.0%。

美国市场预估32亿美元，中国预估复合年增率7.7%

预计2023年美国内分泌检测市场规模将达32亿美元。中国作为全球第二大经济体，预计2030年市场规模将达到38亿美元，2023年至2030年的分析期间复合年增长率为7.7%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 2.5% 和 4.7%。在欧洲，德国的复合年增长率预计为 2.9%。

全球内分泌检测市场—主要趋势和驱动因素总结

内分泌检测将如何彻底改变医疗保健和疾病管理？

内分泌检测透过提供对人体荷尔蒙系统功能的重要洞察，正在彻底改变医疗保健和疾病管理，荷尔蒙系统在调节新陈代谢、生长、繁殖和整体健康方面发挥着重要作用。此类测试透过分析血液、尿液和唾液样本来测量荷尔蒙水平，从而帮助诊断、监测和管理各种内分泌疾病，包括糖尿病、甲状腺疾病、肾上腺功能不全和生殖健康问题。准确检测和监测荷尔蒙失衡对于有效治疗至关重要。检测技术的进步使内分泌检测变得更加准确、方便和全面，使医疗保健提供者能够更早地诊断病情、更有效地制定治疗方案并更准确地监测进展情况，现在您可以了。随着我们对内分泌系统了解的加深及其与肥胖、心血管疾病和骨质疏鬆症等慢性疾病的关係变得更加清晰，内分泌检测作为预防和个人化医疗的基石越来越受到关注。

哪些创新将改善内分泌检测的功能？

内分泌检测领域的创新正在透过诊断技术、自动化和个人化医疗的进步来增强其能力。最重要的进步之一是引入了灵敏且特异性的测定方法，例如免疫测量和质谱法。这些先进的检测方法减少了假阳性和假阴性的可能性，并提供更可靠的诊断资讯。内分泌检测实验室的自动化也是一项重要的创新，能够以最少的人为干预实现样本的高通量处理。这不仅加快了检查过程，还减少了人为错误的可能性，并确保结果一致和准确。此外，内分泌检测与个人化医疗方法的结合正在改变荷尔蒙相关疾病的治疗方式。透过将荷尔蒙水平资料与遗传、生活方式和环境因素相结合，医疗保健提供者可以製定量身定制的治疗计划，以满足每位患者的独特需求，改善治疗结果，并降低併发症的风险。此外，针对特定激素（例如皮质醇和甲状腺刺激素（TSH））的家庭检测套组的开发使内分泌测试变得更容易为公众所接受，使个人能够方便、频繁地监测自己的激素水平。这些创新使内分泌检测更加准确、有效率、以患者为中心，推动内分泌疾病诊断和管理的改善。

内分泌测试如何影响疾病管理和病患结果？

内分泌检测透过实现早期诊断、有针对性的治疗和持续监测荷尔蒙相关疾病，对疾病管理和患者结果产生重大影响。及早发现甲状腺功能亢进、糖尿病和肾上腺功能不全等内分泌疾病可以及时干预，防止疾病进展并降低严重併发症的风险。例如，透过内分泌检测及早发现甲状腺功能障碍可以预防因甲状腺疾病未经治疗而导致的併发症，例如心臟病和心理健康问题。在糖尿病等慢性疾病的治疗中，定期进行内分泌检测对于监测血糖值并根据需要调整治疗计划至关重要，以保持最佳的血糖控制并预防神经病变等併发症。准确测量和监测荷尔蒙水平的能力也使医疗保健提供者能够微调治疗，确保精确的药物剂量并根据个人的荷尔蒙状况量身定制治疗。这种个人化的方法不仅提高了治疗效果，也提高了患者的依从性和满意度。透过提供关键资讯来指导内分泌疾病的管理，内分泌检测在改善患者的治疗结果和生活品质方面发挥关键作用。

推动内分泌检测市场成长的趋势是什么？

多种趋势正在推动内分泌检测市场的成长，包括内分泌疾病盛行率的上升、诊断技术的进步以及对预防性医疗保健日益增长的兴趣。全球糖尿病、甲状腺疾病和METABOLIC INC.症候群等疾病的增加，需要持续监测和管理，推动了对准确、全面的内分泌检测的需求。人口老化也促进了这一增长，因为老年人更容易受到荷尔蒙失衡和相关疾病的影响。次世代定序和免疫检测检测等诊断技术的进步使内分泌检测更加准确、高效和广泛使用，进一步推动了市场扩张。对预防保健的日益重视也是一个重要因素。这是因为早期发现和管理荷尔蒙失衡对于预防慢性病的发作和改善长期健康结果至关重要。此外，内分泌测试与数位健康平台和远端医疗的整合正在扩大这些测试的使用范围，并实现远端监控和咨询，特别是对于服务不足和农村地区的患者来说是有益的。此外，透过将内分泌检测与遗传和生活方式资料相结合来定制治疗的个人化医疗的发展，正在增加内分泌检测作为个人化医疗工具的吸引力。这些趋势凸显了内分泌检测在现代医疗保健中日益重要，内分泌检测已成为疾病预防、管理和个人化治疗策略的核心组成部分。

受访企业范例（总合31 家知名企业）

  • Agilent Technologies, Inc.
  • Apollo Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Dartmouth-Hitchcock
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • HCA Healthcare UK
  • Holston Medical Group
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP11785

Global Endocrine Testing Market to Reach US$16.9 Billion by 2030

The global market for Endocrine Testing estimated at US$12.0 Billion in the year 2023, is expected to reach US$16.9 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Tandem Mass Spectrometry Technology, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Immunoassay Technology segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 7.7% CAGR

The Endocrine Testing market in the U.S. is estimated at US$3.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Endocrine Testing Market - Key Trends and Drivers Summarized

How Is Endocrine Testing Revolutionizing Healthcare and Disease Management?

Endocrine testing is revolutionizing healthcare and disease management by providing critical insights into the functioning of the body’s hormonal system, which plays a vital role in regulating metabolism, growth, reproduction, and overall well-being. This type of testing involves analyzing blood, urine, or saliva samples to measure hormone levels, which can help diagnose, monitor, and manage various endocrine disorders, such as diabetes, thyroid diseases, adrenal insufficiencies, and reproductive health issues. The accurate detection and monitoring of hormone imbalances are essential for effective treatment, as even small deviations from normal levels can significantly impact a person’s health. With advancements in testing technologies, endocrine testing has become more precise, accessible, and comprehensive, allowing healthcare providers to diagnose conditions earlier, tailor treatments more effectively, and monitor progress with greater accuracy. As the understanding of the endocrine system deepens and its link to chronic diseases like obesity, cardiovascular diseases, and osteoporosis becomes clearer, endocrine testing is increasingly seen as a cornerstone of preventive and personalized medicine.

What Innovations Are Enhancing the Functionality of Endocrine Testing?

Innovations in endocrine testing are enhancing its functionality through advancements in diagnostic technologies, automation, and personalized medicine. One of the most significant developments is the introduction of highly sensitive and specific assays, such as immunoassays and mass spectrometry, which allow for the accurate quantification of even minute hormone levels in the body. These advanced assays reduce the likelihood of false positives and negatives, providing more reliable diagnostic information. Automation in endocrine testing labs is another key innovation, enabling high-throughput processing of samples with minimal human intervention. This not only speeds up the testing process but also reduces the potential for human error, ensuring consistent and accurate results. Additionally, the integration of endocrine testing with personalized medicine approaches is transforming the way hormone-related conditions are managed. By combining hormone level data with genetic, lifestyle, and environmental factors, healthcare providers can create tailored treatment plans that address the unique needs of each patient, improving outcomes and reducing the risk of complications. Furthermore, the development of at-home testing kits for certain hormones, such as cortisol or thyroid-stimulating hormone (TSH), is making endocrine testing more accessible to the general public, allowing individuals to monitor their hormone levels conveniently and frequently. These innovations are making endocrine testing more precise, efficient, and patient-centered, driving improvements in the diagnosis and management of endocrine disorders.

How Does Endocrine Testing Impact Disease Management and Patient Outcomes?

Endocrine testing has a profound impact on disease management and patient outcomes by enabling early diagnosis, targeted treatment, and ongoing monitoring of hormone-related conditions. Early detection of endocrine disorders, such as hyperthyroidism, diabetes, or adrenal insufficiency, allows for timely intervention, which can prevent the progression of the disease and reduce the risk of severe complications. For example, identifying thyroid dysfunction early through endocrine testing can prevent complications like heart disease or mental health issues that may arise from untreated thyroid disorders. In managing chronic conditions like diabetes, regular endocrine testing is essential for monitoring blood glucose levels and adjusting treatment plans as needed, helping to maintain optimal blood sugar control and prevent complications such as neuropathy or cardiovascular disease. The ability to measure and monitor hormone levels accurately also allows healthcare providers to fine-tune treatments, ensuring that medications are dosed correctly and that therapies are tailored to the individual’s hormonal profile. This personalized approach not only improves the effectiveness of treatment but also enhances patient compliance and satisfaction, as treatments are more likely to align with the patient’s specific needs and lifestyle. By providing critical information that guides the management of endocrine disorders, endocrine testing plays a vital role in improving patient outcomes and quality of life.

What Trends Are Driving Growth in the Endocrine Testing Market?

Several trends are driving growth in the endocrine testing market, including the rising prevalence of endocrine disorders, advancements in diagnostic technologies, and the increasing focus on preventive healthcare. The global rise in conditions such as diabetes, thyroid disorders, and metabolic syndromes is fueling demand for accurate and comprehensive endocrine testing, as these conditions require ongoing monitoring and management. The aging population is also contributing to this growth, as older adults are more susceptible to hormone imbalances and related diseases. Advancements in diagnostic technologies, such as next-generation sequencing and advanced immunoassays, are making endocrine testing more accurate, efficient, and widely available, further driving market expansion. The growing emphasis on preventive healthcare is another key factor, as early detection and management of hormone imbalances are critical in preventing the onset of chronic diseases and improving long-term health outcomes. Additionally, the integration of endocrine testing with digital health platforms and telemedicine is expanding access to these tests, allowing for remote monitoring and consultation, which is particularly beneficial for patients in underserved or rural areas. The development of personalized medicine approaches, which combine endocrine testing with genetic and lifestyle data to tailor treatments, is also enhancing the appeal of endocrine testing as a tool for individualized care. These trends highlight the increasing importance of endocrine testing in modern healthcare, as it becomes a central component of disease prevention, management, and personalized treatment strategies.

Select Competitors (Total 31 Featured) -

  • Agilent Technologies, Inc.
  • Apollo Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Dartmouth-Hitchcock
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • HCA Healthcare UK
  • Holston Medical Group
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Endocrine Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Prevalence of Endocrine Disorders Driving Demand for Testing
    • Technological Advancements in Diagnostic Tests Enhancing Accuracy and Speed
    • Integration of Telehealth and Remote Testing Options Expanding Accessibility
    • Impact of Lifestyle Diseases on the Growing Need for Endocrine Testing
    • Developments in Biomarker Discovery and Its Application in Endocrine Disorders
    • Future Outlook: AI Integration in Diagnostic Workflows for Endocrine Disorders
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Insulin Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Insulin Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Insulin Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Estradiol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Estradiol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Estradiol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Tandem Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Immunoassay Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Clinical Chemistry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Clinical Chemistry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Clinical Chemistry Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Monoclonal & Polyclonal Antibody Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Monoclonal & Polyclonal Antibody Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Monoclonal & Polyclonal Antibody Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Sensors Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Sensors Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Sensors Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Endocrine Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • JAPAN
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • CHINA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • EUROPE
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Endocrine Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • GERMANY
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Spain 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Russia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Endocrine Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Australia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • INDIA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: India 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: South Korea 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Endocrine Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Latin America 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Argentina 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Brazil 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Mexico 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Rest of Latin America 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Endocrine Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Middle East 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Iran 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Israel 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Saudi Arabia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: UAE 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Rest of Middle East 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • AFRICA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Africa 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030

IV. COMPETITION